Currentculinary health fundPolicy N/A

Alpha1-Proteinase Inhibitor (AAT) Augmentation Therapy — Coverage Criteria

Governance of prior authorization and medical necessity criteria for intravenous alpha1-proteinase inhibitor products for adults with AAT deficiency-related emphysema or panniculitis; affects prescribers and medical benefit payers/approvers.

Policy Summary

Payerculinary health fund

PolicyAlpha1-Proteinase Inhibitor (AAT) Augmentation Therapy — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateDec 3, 2025

Key ActionObtain prior authorization and document age ≥18, baseline serum AAT (<11 mcM or equivalent) with test method, and prescriber statement that the patient is a current non-smoker for emphysema/COPD indication.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yearinitial approval duration

60 mg/kg wklystandard approved dosing

<11 mcMlaboratory threshold

≥18age requirement

Coverage and Medical Necessity Criteria

Policy Summary

Payerculinary health fund

PolicyAlpha1-Proteinase Inhibitor (AAT) Augmentation Therapy — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateDec 3, 2025

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial FDA-Approved Indication

Approve for 1 year if the patient meets ALL of the following (A, B, and C):

FDA-Approved Indication: AAT Deficiency with Emphysema/COPD: A) Patient is >= 18 years of age; AND B) Baseline (pretreatment) alpha1-antitrypsin serum concentration of < 11 mcM (11 micromol/L) (equivalent: < 80 mg/dL by radial immunodiffusion or < 57 mg/dL by nephelometry); AND C) According to the prescriber, the patient is a current non-smoker.< 11 mcM (see lab equivalents)

Dosing: 60 mg/kg IV once weekly; approve for 1 year.

Panniculitis

Approve for 1 year if the patient meets the following:

AAT Deficiency-Associated Panniculitis: Patient is >= 18 years of age with clinical diagnosis of AAT deficiency-associated panniculitis.none specified

Dosing: 60 mg/kg IV once weekly; approve for 1 year. Evidence: augmentation therapy is a reasonable option for AAT deficiency-associated panniculitis.

Alpha1-proteinase inhibitor augmentation therapy is not recommended for patients with AAT deficiency who do not have lung disease, including those with isolated hepatic disease. The ATS/ERS guidance indicates the pathophysiology of liver disease differs from lung disease and there is no evidence that augmentation benefits AAT-related liver disease.

Augmentation therapy is also not recommended for patients with bronchiectasis in the absence of documented alpha1-antitrypsin deficiency; available studies have not shown benefit and bronchiectasis may reflect parenchymal changes rather than AAT deficiency itself.

Requests for alpha1-proteinase inhibitor for indications outside the recommended authorization criteria are not recommended for approval and may be denied; criteria will be updated if new published data become available.

The use of alpha1-proteinase inhibitor for COPD that is unrelated to alpha1-antitrypsin deficiency is explicitly not recommended and considered not medically necessary. Although guideline discussions note potential candidate subgroups among never- or never/current smokers with certain FEV1 ranges, augmentation therapy is indicated only for COPD caused by AAT deficiency and should not be used for COPD from other causes.

Laboratory Thresholds and Coding Values

inv-05: Serum alpha1-antitrypsin level — protective threshold and equivalent lab method values

Protective serum threshold< 11 micromol/L (11 mcM)

Equivalent — radial immunodiffusion< 80 mg/dL (radial immunodiffusion)

Equivalent — nephelometry< 57 mg/dL (nephelometry)

inv-13: Protective threshold / lab equivalents — restatement of 11 mcM and method equivalents

Protective threshold restatementProtective serum threshold = 11 micromol/L (11 mcM)

Radial immunodiffusion equivalent< 80 mg/dL when measured by radial immunodiffusion

Nephelometry equivalent< 57 mg/dL when measured by nephelometry

Prior Authorization, Documentation, and Operational Rules

Prior Authorization

Prior Authorization Recommended

Prior Authorization is recommended for medical benefit coverage of alpha1-proteinase inhibitor. Approvals are recommended for patients who meet the criteria below and are issued for 1 year. Requests for doses outside the dosing documented in this policy (non-standard dosing) will be considered on a case-by-case basis by a clinician (e.g., Medical Director or Pharmacist).

Automation: None
Approvals: 1 year

Step Therapy

Step Therapy / Dosing Exceptions

No step therapy is required for alpha1-proteinase inhibitor. Non-standard dosing or requests that deviate from the policy dosing (including higher or more frequent doses) will be evaluated on a case-by-case basis and require clinical justification; final determination will be made by a clinician (Medical Director or Pharmacist).

Step therapy: None required
Dosing exceptions: Case-by-case review; clinical justification required

Documentation Required

Panniculitis Documentation

For requests for augmentation therapy for AAT deficiency-associated panniculitis, documentation must demonstrate the patient is ≥ 18 years of age and has a clinical diagnosis of panniculitis associated with alpha1-antitrypsin deficiency. Provide supporting clinical documentation from the prescriber confirming the diagnosis and indication.

Required: Age ≥ 18 years
Required: Clinical diagnosis of AAT deficiency-associated panniculitis documented by the prescriber

Clinical Background

Alpha1-antitrypsin (AAT) deficiency is an inherited disorder characterized by abnormally low concentrations of AAT, a protease inhibitor that protects the lung parenchyma. The deficiency predisposes affected adults to progressive emphysema and related COPD; augmentation therapy aims to replace AAT to slow emphysema progression by raising serum AAT toward a theoretical protective threshold. Augmentation is not effective for patients without lung disease and is not indicated for AAT-related hepatic disease.

Key Definitions

inv-12: AAT deficiency — definition entry

TermAlpha1-antitrypsin (AAT) deficiency

DefinitionA rare, chronic, hereditary, autosomal co-dominant disorder marked by low concentrations of AAT leading to progressive emphysema; diagnosis begins with quantitative measurement of AAT levels in plasma.

Clinical threshold noteA serum AAT level below 80 mg/dL (11 micromol/L) is suggestive of AAT deficiency; treatment aims to raise levels above the protective threshold of 11 mcM.